Abstract: A method for detecting anti-filaggrin-autoantibodies specific to rheumatoid arthritis in a biological sample, by providing a filaggrin with no citrulline residues (FNC) having an arginine residue or a filaggrin peptide with no citrulline residues (PFNC) having an arginine residue. Also provided are a citrulline-containing filaggrin (FC) having the peptide sequence of the FNC where some arginine residues have been converted to citrulline residues or a citrulline-containing peptide (PFC) having the peptide sequence of the PFNC, where at least one arginine residue has been converted to a citrulline residue. The sample is contacted with the FNC or PFNC and the FC or PFC, and the resulting immune complexes are detected and quantified, with a value XNC and XC, respectively. Anti-filaggrin-autoantibodies specific to rheumatoid arthritis are determined to be present in the biological sample if the value of XC is greater than the value of XNC.

Abstract: The invention relates to a recombinant DNA encoding a chimeric recombinant protein, comprising at least two first nucleotide fragments each encoding an epitope region of the HIV-1 virus group M or group O or of the HIV-2 virus, at least a second nucleotide fragment encoding a linking region, at least a third nucleotide fragment encoding an attaching region, characterized in that each first nucleotide fragment encodes at least one immunodominant region of the gp120 glycoprotein of HIV-1, of the gp41 glycoprotein of HIV-1 group M, of the gp41 glycoprotein of HIV-1 group O or of the gp36 glycoprotein of HIV-2. The invention also relates to a recombinant chimeric protein encoded by the DNA defined above, and also to the use of said DNA and/or of said recombinant protein for in vitro diagnosis.

Abstract: The invention concerns a method for detecting rheumatoid arthritis-specific autoantibodies, in a biological sample suspected of containing said autoantibodies and other autoantibodies not specific of rheumatoid arthritis, comprising the following steps: providing filaggrin (FNC) or a citrulline-containing filaggrin derivative (FNC) or a filaggrin peptide (PFNC) comprising at least an arginine residue and said citrulline-containing filaggrin (FC) or said citrulline-containing filaggrin derivative (FC) or said citrulline-containing peptide (PFC); contacting said biological sample with said filaggrin (FNC) or said filaggrin derivative (FNC) or said peptide (PFNC) and said filaggrin (FC) or said filaggrin derivative (FC) or said peptide (PFC) in conditions suitable for the formation of immune complexes with the autoantibodies; detecting and quantifying the immune complexes formed between the autoantibodies or the other antibodies present in the sample and said filaggrin (FNC) or said filaggrin derivative (FNC) or

Abstract: A cassette that functions in yeast cells allowing and controlling expression of HBc Ag, HBc Ag fragments and/or recombinant HBc Ag; a reagent for detection and/or monitoring of HBV infections that relies on a product of the cassette; processes for producing monoclonal and/or polyclonal antibodies to the product of the cassette; and processes for (1) diagnosis, (2) vaccine production, (3) vaccination, (4) pharmaceutical production and (5) treatment that rely on the product of the cassette and/or the monoclonal and/or polyclonal antibodies to the product of the cassette.